New drugs of two pharmaceutical enterprises in Lianyungang were rated as "generic drugs with clinical value"

[chinapharma.com Enterprise News] recently, "the second (2016) China pharmaceutical innovation brand series selection activity" was announced, "generic drugs with clinical value" entecavir dispersible tablets produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd., and docetaxel injection produced by Jiangsu Hengrui Pharmaceutical Co., Ltd were selected Xiao Wei, chairman of Jiangsu Kangyuan Pharmaceutical Co., Ltd., was approved as an influential innovator It is worth mentioning that the two pharmaceutical companies selected as "clinical value generic drugs" are from Lianyungang City (new drugs of Lianyungang two pharmaceutical companies were rated as "generic drugs with clinical value" picture source: Baidu picture) it is understood that "China Pharmaceutical Innovation influential brand series selection activity" was jointly established in 2015, with the contribution rate of clinical, economic and social values as the measurement standard, It is a national pharmaceutical industry selection activity to select and commend the "Chinese brand" drugs, enterprises and people who have made outstanding contributions to Chinese pharmaceutical innovation According to the shortlist of each award, under the leadership of academicians Chen Kaixian, Wang Guangji and Chen Jianfeng, the evaluation committee carefully reviewed the shortlisted projects in strict accordance with the evaluation criteria of the contribution rate of "clinical, economic and social value", and combined with the results of the online public recommendation, selected and issued three clinical value innovative drugs and four innovative pharmaceutical enterprises, There are 4 influential innovators and 3 generic drugs with clinical substitution value The two "clinical value generic drugs" selected by Lianyungang City are the recognition of experts and society to the city, as well as the recognition of the clinical value of products Taking chinda Tianqing entecavir as an example, the drug is a new generation of oral guanine nucleoside analogues for the treatment of hepatitis B virus infection It is a first-line anti hepatitis B drug recommended by the United States liver disease guidelines, European liver disease guidelines, Asia Pacific liver disease guidelines, who chronic hepatitis B prevention guidelines Zhengda Tianqing is a domestic enterprise that has obtained the production qualification of entecavir dispersible tablets, and has fully independent intellectual property rights for synthesis methods and preparation inventions It has applied for 17 inventions, 9 of which have been authorized According to "medical geography" data, "Runzhong" is a Chinese brand selected in the top 10 of global antiviral drugs In 2016, the sales volume of "Runzhong" has exceeded 3.5 billion yuan, covering 3000 hospitals in more than 30 provinces and cities across the country, accumulating 2 million patients, leaping to the top with 42% market share (IMS data) The two selected drugs are only a microcosm of the development of Lianyungang pharmaceutical industry, said the relevant person in charge of the SFDA In the past 30 years, Lianyungang pharmaceutical enterprises have always adhered to the concept of innovation driven and quality-oriented, focused on anti-tumor, anti infection, liver disease, gynecological diseases and other fields, created a series of star products, and gradually become the leading enterprises in these fields These drugs have not only witnessed the development of Lianyungang enterprises, but also greatly reduced the cost of patients' treatment and reduced the cost of Chinese people's medical treatment.